Novel Implications of MicroRNAs, Long Non-coding RNAs and Circular RNAs in Drug Resistance of Esophageal Cancer

Wei, Ling; Sun, Jian; Zhang, Nasha; Shen, Yue; Wang, Teng; Li, Zengjun; Yang, Ming

doi:10.3389/fcell.2021.764313

Cited by 10 publications

(7 citation statements)

References 133 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, epigenetics and non-coding RNAs play a critical role in EC-related multidrug resistance and affect the effectiveness of therapies. In fact, EC’s susceptibility to recurrence, metastasis, and drug resistance development after first-line treatment, highlights the urgent requirement for optimizing the medicine regimen ( Liu et al, 2021 ; Wei et al, 2021 ).…”

Section: Current Gastrointestinal Cancers Therapies Challenges and Li...mentioning

confidence: 99%

Current trends and future prospects of drug repositioning in gastrointestinal oncology

Fatemi,

Karimpour,

Bahrami

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Gastrointestinal (GI) cancers comprise a significant number of cancer cases worldwide and contribute to a high percentage of cancer-related deaths. To improve survival rates of GI cancer patients, it is important to find and implement more effective therapeutic strategies with better prognoses and fewer side effects. The development of new drugs can be a lengthy and expensive process, often involving clinical trials that may fail in the early stages. One strategy to address these challenges is drug repurposing (DR). Drug repurposing is a developmental strategy that involves using existing drugs approved for other diseases and leveraging their safety and pharmacological data to explore their potential use in treating different diseases. In this paper, we outline the existing therapeutic strategies and challenges associated with GI cancers and explore DR as a promising alternative approach. We have presented an extensive review of different DR methodologies, research efforts and examples of repurposed drugs within various GI cancer types, such as colorectal, pancreatic and liver cancers. Our aim is to provide a comprehensive overview of employing the DR approach in GI cancers to inform future research endeavors and clinical trials in this field.

show abstract

Section: Current Gastrointestinal Cancers Therapies Challenges and Li...mentioning

confidence: 99%

Current trends and future prospects of drug repositioning in gastrointestinal oncology

Fatemi,

Karimpour,

Bahrami

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Albeit the mechanisms of platinum drug resistance have been the subject of numerous investigations, few efficient, targeted treatments are available ( 200 – 202 ). Mounting evidence suggests that circRNAs are involved in multiple cellular processes and malignancies, including ESCC ( 203 , 204 ). Understanding the underlying causes of chemoresistance is crucial for developing effective ESCC treatments and preventing recurrence.…”

Section: Clinical Application Of Circrna In Esccmentioning

confidence: 99%

Roles of circRNA dysregulation in esophageal squamous cell carcinoma tumor microenvironment

Yao

Cai

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Esophageal squamous cell carcinoma (ESCC) is the most prevalent histological esophageal cancer characterized by advanced diagnosis, metastasis, resistance to treatment, and frequent recurrence. In recent years, numerous human disorders such as ESCC, have been linked to abnormal expression of circular RNAs (circRNAs), suggesting that they are fundamental to the intricate system of gene regulation that governs ESCC formation. The tumor microenvironment (TME), referring to the area surrounding the tumor cells, is composed of multiple components, including stromal cells, immune cells, the vascular system, extracellular matrix (ECM), and numerous signaling molecules. In this review, we briefly described the biological purposes and mechanisms of aberrant circRNA expression in the TME of ESCC, including the immune microenvironment, angiogenesis, epithelial-to-mesenchymal transition, hypoxia, metabolism, and radiotherapy resistance. As in-depth research into the processes of circRNAs in the TME of ESCC continues, circRNAs are promising therapeutic targets or delivery systems for cancer therapy and diagnostic and prognostic indicators for ESCC.

show abstract

“…Nonetheless, chemotherapy resistance is still the biggest factor limiting the clinical application of 5-FU in EC, and its molecular mechanism is complex and changeable 21 . Accumulating evidence has shown that lncRNA is becoming a star molecule affecting tumor chemotherapy 22 , 23 . Similarly, many articles verify the critical effect of lncRNA on 5-FU sensitivity in EC 24 – 26 .…”

Section: Introductionmentioning

confidence: 99%

Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway

Tan

Liu

Wang

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Chemotherapy was the main treatment method for esophageal cancer (EC) patients. However, chemotherapy resistance due to multiple factors is a major barrier to EC treatment. For investigating how small nucleolar RNA host gene 6 (SNHG6) affected the 5-fluorouracil (5-FU) resistance in EC as well as its possible molecular mechanism. This work conducted cell viability assay, clone formation, scratch assays together with cell apoptosis for evaluating the roles of SNHG6 and enhancer of zeste homolog 2 (EZH2, the histone-lysine N-methyltransferase). Relevant molecular mechanism was identified by RT-qPCR analysis together with Western-blot (WB) assays. Our data showed that SNHG6 expression increased in EC cells. SNHG6 promotes colony formation and migration, whereas suppresses EC cell apoptosis. SNHG6 silencing markedly promoted 5-FU-mediated suppression on KYSE150 and KYSE450 cells. Additional mechanism studies showed that SNHG6 modulating STAT3 and H3K27me3 via promoting EZH2 level. Similar to the function of SNHG6, abnormal expression of EZH2 promotes the malignancy of EC and intensifies its resistance to 5-FU. In addition, overexpression of EZH2 abolished the role of SNHG6 silencing in 5-FU sensitivity in EC cells. SNHG6 overexpression promoted malignancy of EC and increased EC cell resistance to 5-FU. Besides, further molecular mechanism studies provided a novel regulatory pathways that SNHG6 knockdown promoted EC cell sensitivity to 5-FU by modulating STAT3 and H3K27me3 via promoting EZH2 expression.

show abstract

Novel Implications of MicroRNAs, Long Non-coding RNAs and Circular RNAs in Drug Resistance of Esophageal Cancer

Cited by 10 publications

References 133 publications

Current trends and future prospects of drug repositioning in gastrointestinal oncology

Current trends and future prospects of drug repositioning in gastrointestinal oncology

Roles of circRNA dysregulation in esophageal squamous cell carcinoma tumor microenvironment

Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway

Contact Info

Product

Resources

About